Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: A Retrospective Review and Survival Analysis at a Single Academic Institution
- PMID: 39760391
- DOI: 10.1097/DSS.0000000000004536
Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: A Retrospective Review and Survival Analysis at a Single Academic Institution
Abstract
Background: Prognostication of atypical spindle cell neoplasms, including atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS), is challenging; outcomes vary widely, and further identification of prognostic features is crucial.
Objective: To evaluate prognostic factors that may portend worse outcomes in patients with AFX and PDS.
Materials and methods: A retrospective chart review of patients with AFX and PDS was conducted. Data were analyzed using Pearson chi square and T -test. Survival was analyzed using the Kaplan-Meier estimate. A stepwise cox proportional hazards model was created to identify variables associated with increased risk of poor outcomes.
Results: Thirty-four patients with AFX and 10 patients with PDS were identified. PDS had a 60% overall mortality rate (vs 26.5% in AFX), a larger preoperative size of 8.9 cm 2 (vs 2.4 cm 2 ) ( p < .0001), and a 50% recurrence rate (vs 5.9%) ( p = .0039). Female gender (HR 22.18 95% CI 2.54-194.13; p = .001), immunosuppression (HR 5.02 95% CI 1.32-19.12; p = .0044), and perineural invasion (PNI) (HR 78.46 3.97-1,549.56; p = .0091) were associated with increased risk of poor outcomes.
Conclusion: Few large studies have examined clinical features that portend worse outcomes. The authors identify female gender, immunosuppression, and PNI as variables associated with increased risk of recurrence or death.
Copyright © 2025 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Llombart B, Serra-Guillén C, Requena C, Alsina M, et al. Leiomyosarcoma and pleomorphic dermal sarcoma: guidelines for diagnosis and treatment. Actas Dermosifiliogr (Engl Ed) 2019;110:4–11.
-
- Cohen PR. Cutaneous undifferentiated pleomorphic sarcoma is a pleomorphic dermal sarcoma. Dermatol Online J 2020;26:13030.
-
- Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012;36:1317–26.
-
- Tardío JC, Pinedo F, Aramburu JA, Suárez-Massa D, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol 2016;43:101–12.
-
- Helbig D, Ihle MA, Pütz K, Tantcheva-Poor I, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 2016;7:21763–74.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous